We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




New Pain Therapy Reverses Glial Activation

By HospiMedica staff writers
Posted on 17 Dec 2003
Researchers believe that delivering the gene for interleukin-10 (IL-10) to the affected region may reverse glial activation and relieve chronic pain. More...
Their findings from a number of studies showing proof of principle were presented at the annual meeting of the Society of Neuroscience in New Orleans (LA, USA).

Glial cells have an important role in pain. When they are activated in response to nerve damage, tumors, or viruses, they produce increased levels of substances that enhance the neuron's response to pain signals. These substances then activate other glia. When a critical level is reached, it produces a self-perpetuating feedback loop that can continue even after the original cause of pain has been resolved. The researchers have focused on the effectiveness of the powerful, naturally occurring anti-inflammatory protein IL-10 to block or reverse glial activation. Studies in rats have demonstrated that it can prevent or reverse every enhanced pain state examined to date.

"A new model for the etiology of chronic pain is quickly emerging as researchers around the world are developing a better understanding of the underlying causes of chronic pain,” said Linda Watkins, Ph.D., professor in the department of psychology and the Center for Neuroscience at the University of Colorado at Boulder (USA; www.colorado.edu) and co-author of a paper published in the December 1, 2003, issue of Nature Reviews Drug Discovery. Dr. Watkins and colleagues are working with Avigen, Inc. (San Francisco, CA, USA) on the development of a new pain treatment.




Related Links:
U. of Colorado

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Head Rest
Medifa 61114_3
Pressure Guidewire
SavvyWire
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.